We think that there might be two explanations: 1) The loading efficiency of miR‐574‐5p and miR‐574‐3p onto RISC with Ago2 may be different after miRNAs entering CM and CF cells via nanoparticle delivery; 2) The function and contribution of full spectrum of individual targets of miR‐574‐5p and miR‐574‐3p may play a differential role in cardiac remodeling (e.g., in hypertrophy versus fibrosis). Here, AGO2 is linked to hypertrophy.